One year into its Nascar Sprint Cup experiment, Toyota took new driver Kyle Busch on a tour of its offices and plants. Not in Honshu or Hokkaido, but rather California, Texas and Kentucky.
The "too-good-to-be-true" era of abundant demand and limited supply is coming to an end.
Orders for U.S. business equipment climbed more than forecast in October, indicating steady domestic demand is encouraging corporate investment even as global sales waver.
Philippine regulators will investigate accidents involving Mitsubishi Motors Corp.’s Montero Sport vehicles after complaints they can speed out of control.
Survey estimates $1 billion VW-related economic cost
There's one thing Republicans and Democrats vying for their parties' nomination for president in 2016 seem to agree on, the evil of Wall Street. Bloomberg View columnist Al Hunt and David Barse, chief executive officer at Third Avenue Management, examine the rhetoric on both sides of the aisle on "Bloomberg ‹GO›." (Hunt is a Bloomberg View columnist. The opinions expressed are his own.) (Source: Bloomberg)
Wall Street banks may be close to winning one of their biggest lobbying fights this year by beating back U.S. requirements that would have led to billions of dollars of additional costs on derivatives trading.
The morning after cancer-center firm 21st Century Oncology Inc. cut its earnings forecast for 2015 last week, money manager Rajay Bagaria woke up to find his holdings of the junk-rated company’s bonds had lost 19 percent of their market value overnight.
Blackstone Group LP is in talks to sell four Los Angeles office towers to a group led by Douglas Emmett Inc. for more than $1 billion, according to a person with knowledge of the negotiations.
The Federal Reserve said it’s setting tougher standards for examiners of the biggest U.S. banks, following criticism by lawmakers that the agency has been captured by the Wall Street firms it supervises.
Abengoa SA’s bonds and stock tumbled to records after the embattled renewable-energy company said it was seeking preliminary protection from creditors following the breakdown of talks with a new investor. Third Avenue Management CEO David Barse speaks on "Bloomberg ‹GO›." (Source: Bloomberg)
Och-Ziff Capital Management and Man Group Plc’s GLG unit were among at least five hedge funds to profit as Abengoa SA, a Spanish renewable-energy company, fell as much as 69 percent Wednesday.
Bloomberg View's Barry Ritholtz and Bloomberg Intelligence's Richard Yamarone discuss retailing and the state of the U.S. economy. They speak on "Bloomberg ‹GO›." Ritholtz's opinions are his own. (Source: Bloomberg)
Household spending rose less than forecast in October, showing the biggest part of the U.S. economy was off to a slow start heading into the holiday shopping season.
On the largest island in Australia’s Great Barrier Reef World Heritage Area, $60 billion of liquefied natural gas terminals are helping feed China’s hunger for energy. The next major construction project may appeal to its tourists.
John Zuccotti, a former New York City deputy mayor and chairman of global operations for Brookfield Asset Management Inc. who oversaw landmark Manhattan properties including the World Financial Center, has died. He was 78.
An arm of Nicholas Schorsch’s investment empire pressured employees into rigging shareholder proxy votes, Massachusetts’ securities regulator alleged in a complaint filed Thursday.
Deutsche Bank AG sold a property in central Frankfurt that’s set to become the German city’s biggest construction site to a local developer.
Commodities trader Michael Coscia was found guilty in a major victory for the government in its first test of a criminal spoofing law at trial.
Michael Coscia began testifying in his own defense in the first-ever “spoofing” prosecution, in which he is charged with making $1.4 million by illegally playing both sides of the market.
A hedge fund that has long been bearish on Valeant Pharmaceuticals International Inc. published a new list of pharmacies it said were probably tied to the drugmaker, briefly sending Valeant shares down Wednesday.
U.S. stocks fluctuated in pre-holiday trading, with equities hovering near three-week highs as investors weighed mixed economic data and weakness in commodities.
Mylan NV, bruised by its acrimonious and ultimately unsuccessful bid to buy Perrigo Co., is likely to find itself now competing with the drugmaker for other assets.
Turing Pharmaceuticals AG, the drugmaker that raised the price of an anti-infective drug Daraprim by more than 5,000 percent, suggested that it won’t cut the drug’s list price, instead offering to negotiate discounts with hospitals.
A second round of mergers and acquisitions awaits Spain’s banking industry, three years after Europe’s debt crisis set off the biggest exodus in the country’s history.